These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 12878526)

  • 1. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
    Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.
    Croisier D; Etienne M; Bergoin E; Charles PE; Lequeu C; Piroth L; Portier H; Chavanet P
    Antimicrob Agents Chemother; 2004 May; 48(5):1699-707. PubMed ID: 15105123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
    Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
    Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
    Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
    Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
    Homma T; Hori T; Sugimori G; Yamano Y
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
    Browne FA; Clark C; Bozdogan B; Dewasse BE; Jacobs MR; Appelbaum PC
    Int J Antimicrob Agents; 2002 Aug; 20(2):93-9. PubMed ID: 12297357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
    Garrison MW; Schimmels JA; Madaras-Kelly KJ
    Diagn Microbiol Infect Dis; 2003 Dec; 47(4):587-93. PubMed ID: 14711480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
    Pérez-Vázquez M; Román F; Aracil B; Cantón R; Campos J
    J Clin Microbiol; 2004 Mar; 42(3):1185-91. PubMed ID: 15004073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.